Topics

Latest "Signs Symptoms" News Stories

10:42 EST 9th December 2019 | BioPortfolio

Here are the most relevant search results for "Signs Symptoms" found in our extensive news archives from over 250 global news sources.

More Information about Signs Symptoms on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Signs Symptoms for you to read. Along with our medical data and news we also list Signs Symptoms Clinical Trials, which are updated daily. BioPortfolio also has a large database of Signs Symptoms Companies for you to search.

Showing "Signs Symptoms" News Articles 1–25 of 3,800+

Monday 9th December 2019

Optic Neuropathy Pipeline Review, H1 2019 [Report Updated: 23042019] Prices from USD $1760

Optic Neuropathy Pipeline Review, H1 2019SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuropathy Pipeline Review, H1 2019, provides an overview of the Optic Neuropathy Ophthalmology pipeline landscape.Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisp...


Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 2019

- Key learnings from real-world data are applied as Takeda continues to evolve its hematology portfolio, advancing treatment for the bleeding disorders community - Pre-clinical scientific studies demonstrate potential opportunities to improve upon adeno-associated virus gene therapies for hemophilia and other monogenic diseases Takeda Pharmaceutical Company Limited (

Mistaken identity: Uncovering the Truth about ‘Sebaceous’ Cysts

Dermatologist Robert Levine, MD with Advanced Dermatology PC, Shares Tips on Epidermoid Cysts EAST SETAUKET, N.Y. (PRWEB) December 09, 2019 It’s a longstanding case of getting the name wrong: “The cysts most people contend with are not ‘sebaceous,’” notes Dr. Robert Levine, a dual-board-certified dermatologist with Advanced Dermatology PC. “What we’re actually seeing are usually epi...


Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting

- Four-Year Data Continue to Show Superior Progression-Free Survival of ADCETRIS in Combination with AVD when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma with 31 Percent Reduction in the Risk of Progression or Death - - Additional Analysis from ECHELON-2 Phase 3 Clinical Trial Evaluating ADCETRIS Plus CHP Chemotherapy Also Featured at ASH Annual Meeting -

Centerstone Comics “Spark” Conversations about Top Teen Issues

Latest story from behavioral health care leader confronts prescription drug misuse, dangers of opioids Zap! Crunch! Pow! Centerstone, a national leader in behavioral health care, has released its sixth superhero comic book for students: Spark and the Dangerous Switch. In the series’ latest installment, teen superhero Spark addresses the dangers of opioids and prescription drug misuse. This pre...

Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I

- Initial Data Demonstrated Robust CD18 Expression and Resolution of Disease-Mediated Lesions in Months After Gene Therapy Treatment - Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces preliminary data from its Phase 1/2 clinical trial of RP-L201,...

Mochida Pharmaceutical Co Ltd 4534 Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $110

Mochida Pharmaceutical Co Ltd 4534 Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that...

Health Tip: Heart Attack Symptoms in Women

-- Every 40 seconds, someone in the United States has a heart attack, says the American Heart Association. Women and men can have different symptoms, so it's important to know the hallmarks of a heart attack for each gender. The AHA mentions these...

Sunday 8th December 2019

Rocket Pharmaceuticals Presents Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 “Process B” for Fanconi Anemia at 61st American Society of Hematology Annual Meeting

—US Phase 1 Trial Establishes Feasibility of Commercial “Process B” Vector/Cell Manufacturing in FA— —Preliminary Data Demonstrate Evidence of Early Engraftment Without Conditioning Four to Six Months after Administration of Gene Therapy— —“Process B” Drug Product VCN 2-3x Higher Than That Administered to Optimally-Treated “Process A” Patients—

Aurora Bio, Inc Announces Clinical Data on Lead Program, AUR01, a Novel Systemic Amyloidosis Imaging Tracer, at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition

Analysis of PET images indicated uptake of AUR01 (124I-p5+14) in the heart, kidneys, liver, spleen, pancreas, bone marrow, lung, choroid plexus, pituitary, and adrenal glands of Light chain amyloidosis (AL) patients. Cardiac uptake of the radiotracer was observed in 83% of AL patients, including 50% who had no cardiac symptoms and had normal cardiac biomarkers (NT-probNP <330pg/ml). Kidney, sp...

Blepharitis Pipeline Review, H1 2019 [Report Updated: 23042019] Prices from USD $1760

Blepharitis Pipeline Review, H1 2019SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Blepharitis Pipeline Review, H1 2019, provides an overview of the Blepharitis Ophthalmology pipeline landscape.Blepharitis is an inflammation of the eyelids, usually caused by an excess growth of bacteria that is ordinarily found on the skin, blockage of the eyelid's oil...

Genovis AB GENO Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $110

Genovis AB GENO Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your busin...

Crohn's Disease Regional Enteritis Pipeline Review, H1 2019 [Report Updated: 29042019] Prices from USD $1760

Crohn's Disease Regional Enteritis Pipeline Review, H1 2019SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease Regional Enteritis Pipeline Review, H1 2019, provides an overview of the Crohn's Disease Regional Enteritis Gastrointestinal pipeline landscape.Crohn's disease is an inflammatory bowel disease IBD. It causes inflammation of the lini...

Cerevel Therapeutics Announces Phase 1 Results for CVL-865, a Novel α2/3/5-subtype GABAA Positive Allosteric Modulator in Development to Treat Epilepsy

CVL-865 is the first in a new class of treatments for epilepsy; Data presented at 2019 Annual Meeting of American Epilepsy Society Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today results of a Phase 1 dose-escalation

Hypertension Market Insights, Epidemiology and Market Forecast 2028 [Published by MIReports] Prices from USD $5262

Report Summary"Hypertension Market Insights, Epidemiology and Market Forecast 2028" report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends...

Secondary Hyperparathyroidism Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $1760

Secondary Hyperparathyroidism Pipeline Review, H2 2019SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Secondary Hyperparathyroidism Pipeline Review, H2 2019, provides an overview of the Secondary Hyperparathyroidism Hormonal Disorders pipeline landscape.Secondary hyperparathyroidism is occurs when the parathyroid glands in neck produce too much parathyr...

Saturday 7th December 2019

Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer

Results highlighted in two oral presentations at the American Society of Hematology Annual Meeting The Bristol-Myers Squibb-Pfizer Alliance today announced results from retrospective real-world data analyses reporting outcomes on the safety and effectiveness of Eliquis® (apixaban) compared to low molecular weight heparin (LMWH) or warfarin for the treatment of venous thromboembolism (VTE) in pa...

Seattle Genetics Announces Updated Data of ADCETRIS® (Brentuximab Vedotin) in Combination with OPDIVO® (Nivolumab) in Frontline and Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting

- Additional Analysis in Phase 2 Trial of ADCETRIS plus OPDIVO in Patients with Frontline Hodgkin Lymphoma Aged 60 Years and Older - - Two-Year Follow-up Results from Phase 1/2 Trial in Relapsed Hodgkin Lymphoma - Seattle Genetics, Inc. (Nasdaq:SGEN) today announced updated and long-term follow-up analyses from two clinical trials evalu

Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment

-- 47 Percent of Refractory Large B-cell Lymphoma Patients in ZUMA-1 Pivotal Phase 2 Cohorts Were Alive Three Years after a Single Infusion of Yescarta -- -- Separate Cohort Finds Earlier Steroid Use May Reduce Risk of Severe Cytokine Release Syndrome and Neurologic Events -- Kite, a Gilead Company (Nasdaq: GILD), today announced new data from the ZUMA-1 trial of Yescarta® (axicabtagene cilol...

Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting

Duvelisib Achieves Overall Response Rate of 62% in Patients with Relapsed or Refractory PTCL with Manageable Safety Profile in Initial Phase of PRIMO Trial Data Presented Support Potential of Duvelisib Across Indications, Lines of Therapy and in Combination Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing med...

Genentech Announces New Data on Novel Cd20-cd3 Bispecific Cancer Immunotherapies in People With Difficult-to-Treat Lymphomas

– Mosunetuzumab data to be presented at the American Society of Hematology 2019 Annual Meeting Plenary Scientific Session demonstrate durable complete responses in people with relapsed or refractory non-Hodgkin’s lymphoma – – Preliminary safety and efficacy data for CD20-TCB support potential of combination approaches with anti-CD20 therapies – Genentech, a member of the Roche Group ...

Allergic Rhinitis Immunotherapy: Opportunity Analysis and Forecasts to 2028 [Published by Global Data] Prices from USD $9676

Allergic Rhinitis Immunotherapy: Opportunity Analysis and Forecasts to 2028SummaryAllergic rhinitis AR is a common, IgEmediated inflammatory disease in which an individual reacts to an otherwise innocuous inhaled substance in the environment with one or more of the following symptoms: rhinorrhea, sneezing, nasal congestion, and pruritus of the eyes, nose, and palate. Based on epidemiological analy...

Moromix Company Releases Latest Lineup of Dermatological Resources

Offering information on causes, symptoms and treatments is the key to helping people overcome their skin conditions, publishes moromix.com HOUSTON (PRWEB) December 07, 2019 More than 85 million people across the United States currently suffer from various skin issues according to a recent report from the American Academy of Dermatology, indicating this problem is more common than previously belie...

Elizabethkingia Infection Market Insights, Epidemiology and Market Forecast 2028 [Published by MIReports] Prices from USD $5262

Report Summary"Elizabethkingia Infection Market Insights, Epidemiology and Market Forecast 2028" report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue,...

Cough Pipeline Review, H1 2019 [Report Updated: 29032019] Prices from USD $1760

Cough Pipeline Review, H1 2019SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cough Pipeline Review, H1 2019, provides an overview of the Cough Respiratory pipeline landscape.Cough is a reflex action that clears the throat of mucus or foreign irritants. Signs and symptoms include stuffy nose, hoarseness, wheezing and shortness of breath and heartburn or...


Quick Search

News Quicklinks